Skip to main
  1. Stocks
  2. Celcuity
  3. Forecast
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity is attractive because gedatolisib has produced differentiated clinical results across PIK3CA wild-type and mutant HR+/HER2- breast cancer, including 9.3 months mPFS in wild-type and about 11.1 to 11.3 months in mutant disease, supporting a mutation-agnostic commercial strategy. Its launch fundamentals also look strong, with REVTORPYK available since September 30, 2026, 78% of the top 36 strategic accounts already ordering, 91% of U.S. commercial and Medicare lives covered, and cash of $642.7M funding operations through 2029. Additional upside comes from ongoing Phase 3 VIKTORIA-2 and Phase 1b/2 prostate programs, which broaden the addressable opportunity beyond the initial 2L breast cancer market and reinforce the platform’s pipeline-in-a-product profile.

Bears say

Celcuity is viewed negatively because gedatolisib faces a difficult path to approval and commercialization, with downside risks tied to additional indication failures, regulatory delays, and the need to raise sufficient capital for research and commercial build-out. Even if approved, adoption could be constrained by weekly IV dosing, stomatitis, and buy-and-bill friction, including temporary J-code reimbursement, formulary access, and manufacturing constraints at its sole production site, which may make the launch ramp slower than expected. The competitive backdrop is also unfavorable, as oral rivals and established standards in HR+/HER2- breast cancer and mCRPC can win on convenience or efficacy, while first-line endocrine-sensitive disease remains especially challenging given control arms with median PFS of 25-28 months.

Celcuity (CELC) has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Celcuity (CELC) Analyst Forecast & Price Prediction

Get the latest Celcuity (CELC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Celcuity (CELC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Strong Buy based on their latest research and market trends.

According to 11 analysts, Celcuity (CELC) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $153.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $153.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Celcuity (CELC) Analyst Forecast & Price Prediction

Get the latest Celcuity (CELC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Celcuity (CELC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CELC stock data and trends